Have a feature idea you'd love to see implemented?
Let us know!
ABOS Acumen Pharmaceuticals Inc
Price (delayed)
$2.31
Market cap
$138.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.38
Enterprise value
$135.35M
Highlights
The company's quick ratio has shrunk by 72% YoY and by 41% QoQ
Acumen Pharmaceuticals's net income has plunged by 68% YoY and by 26% from the previous quarter
Key stats
What are the main financial stats of ABOS
Market
Valuations
Earnings
Shares outstanding
60.08M
Market cap
$138.78M
Enterprise value
$135.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$78.06M
EBITDA
-$77.89M
Free cash flow
-$67.34M
Per share
Balance sheet
Liquidity
EPS
-$1.38
Free cash flow per share
-$1.12
Book value per share
$3.62
Revenue per share
$0
TBVPS
$4.44
Total assets
$266.98M
Total liabilities
$49.77M
Debt
$29.99M
Equity
$217.2M
Working capital
$187.72M
Debt to equity
0.14
Current ratio
10.43
Quick ratio
10.07
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-28%
Return on equity
-33%
Return on invested capital
-30.7%
Return on capital employed
-31.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABOS stock price
How has the Acumen Pharmaceuticals stock price performed over time
Intraday
-2.53%
1 week
-11.49%
1 month
-14.44%
1 year
-1.28%
YTD
-39.84%
QTD
-6.85%
Financial performance
How have Acumen Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$92.91M
Net income
-$81.67M
Gross margin
N/A
Net margin
N/A
Acumen Pharmaceuticals's net income has plunged by 68% YoY and by 26% from the previous quarter
Acumen Pharmaceuticals's operating income has shrunk by 63% YoY and by 21% QoQ
Growth
What is Acumen Pharmaceuticals's growth rate over time
Valuation
What is Acumen Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Acumen Pharmaceuticals's EPS has decreased by 23% from the previous quarter and by 23% YoY
The company's equity fell by 23% YoY and by 11% QoQ
The P/B is 18% less than the last 4 quarters average of 0.8
Efficiency
How efficient is Acumen Pharmaceuticals business performance
ABOS's return on equity is down by 38% year-on-year and by 34% since the previous quarter
ABOS's ROIC is up by 31% YoY but it is down by 18% from the previous quarter
ABOS's ROA is down by 28% since the previous quarter and by 22% year-on-year
Dividends
What is ABOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABOS.
Financial health
How did Acumen Pharmaceuticals financials performed over time
The company's quick ratio has shrunk by 72% YoY and by 41% QoQ
ABOS's current ratio has dropped by 71% year-on-year and by 40% since the previous quarter
The company's debt is 86% lower than its equity
The company's equity fell by 23% YoY and by 11% QoQ
The debt to equity has grown by 17% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.